• High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
  • 6 , 9 The demonstrated efficacy, lack of myelosuppression, and overall tolerability of thalidomide provide a strong rationale for its incorporation in standard induction regimens for patients presenting with NDMM who may be eligible for ASCT. (haematologica.org)
  • Combination vincristine, doxorubicin, and dexamethasone (VAD) is considered a standard infusional induction therapy for younger MM patients prior to HDT and ASCT. (haematologica.org)
  • Additional data presented in an oral presentation at ASCO (Abstract #8013) demonstrate that adding BEXXAR to BEAM (BCNU, etoposide, ara-C, and melphalan) chemotherapy as a conditioning regimen prior to autologous stem cell transplant (ASCT) in patients with relapsed or high-risk chemosensitive diffuse large B-cell lymphoma (DLBCL) resulted in 78% of the patients achieving a complete remission following the transplant. (salesandmarketingnetwork.com)
  • 60 years of age (P = 0.0028) and PR at ASCT (P = 0.0013) in AITL patients. (elsevierpure.com)
  • 60 years of age at ASCT (P = 0.0077) in AITL patients were risk factors for OS after ASCT with a chemosensitive PIF status. (elsevierpure.com)
  • Strategies that carefully select PTCL patients may allow identification of individuals suitable for ASCT. (elsevierpure.com)
  • OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). (smw.ch)
  • METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. (smw.ch)
  • Would you recommend autologous stem cell transplantation (ASCT) for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM)? (targetedonc.com)
  • After 90 months of follow-up, the study found an advantage in progression-free survival [PFS] at 47 months vs 35 months for patients who did not receive ASCT. (targetedonc.com)
  • 1,2 One of the issues is that three-quarters of the patients who did not receive ASCT initially had a stem cell transplant at first relapse. (targetedonc.com)
  • Note: For transplant-eligible patients enrolled to Part 1 or Part 2, induction plus conditioning chemotherapy/ASCT +/- maintenance therapy constitute one regimen. (who.int)
  • Safety, tolerability, toxicity management, and supportive care are important aspects of patient counseling in the treatment of diffuse large B-cell lymphoma (DLBCL). (expertperspectives.com)
  • 3 - 5 This report by the Spanish Lymphoma Group (GELTAMO) aims to provide useful guidelines and recommendations for the prevention, diagnosis, and treatment of central nervous system diffuse large B-cell lymphoma patients with, or at risk of, leptomeningeal and/or brain parenchyma lymphoma relapse. (haematologica.org)
  • Several factors hinder the identification of risk factors for central nervous system (CNS) involvement in diffuse large B-cell lymphoma (DLBCL), including the retrospective nature of most studies, the relatively low frequency of CNS relapse in DLBCL, and the heterogeneity of CNS prophylaxis methods used in these studies. (haematologica.org)
  • Malignant blast cells (i.e. diffuse large B-cell lymphoma) are fast-growing and result in aggressive disease, whereas malignant mature lymphocytes (i.e. follicular lymphoma) behave indolently. (oncolink.org)
  • Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). (smw.ch)
  • Non Hodgkin Lymphoma Clinical Trial: A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. (survivornet.com)
  • The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. (survivornet.com)
  • For years we have known that radioimmunotherapy, such as BEXXAR, is an effective treatment for patients with relapsed or refractory lymphoma. (salesandmarketingnetwork.com)
  • The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. (elsevierpure.com)
  • Their disease had been refractory (defined as less than partial response) to one (18 patients) or two (24 patients) regimens of neoadjuvant chemotherapy. (elsevierpure.com)
  • Dr. Tallman focuses on the molecular genetics of APL, current curative treatment strategies and approaches for patients with relapsed and refractory disease. (ashpublications.org)
  • Even though classical Hodgkin lymphoma is highly curable, the outcome of patients with a refractory or relapsed disease has been disappointing. (wjon.org)
  • Immune checkpoint inhibitors such as the anti-programmed death 1 (PD-1) receptor antibodies have recently been approved to treat relapsed and refractory cHL and have significantly improved the outcome of patients with rrcHL. (wjon.org)
  • Even though cHL is highly curable, around 25% of the patients with cHL have a refractory or relapsed disease after the first-line therapy [ 5 ]. (wjon.org)
  • However, in these patients, conventional-dose chemotherapy regimens induce low remission rates, resulting in long-term remissions in approximately 40-50% of relapsed patients and in up to 25-30% of those with primary refractory disease. (wjon.org)
  • The 3 IMiDs, or immunomodulatory drugs, we have approved-thalidomide, lenalidomide, and pomalidomide-are core parts of treatment for both newly diagnosed patients, as well as relapsed and refractory patients. (ajmc.com)
  • In the relapsed setting, there is also significant use of IMiDs, and whether we use lenalidomide or pomalidomide is dependent on whether the patient is refractory to lenalidomide. (ajmc.com)
  • I consider those patients who are progressing on maintenance lenalidomide to be refractory to lenalidomide. (ajmc.com)
  • In the second-line setting, we'll often use the next-generation IMiD or a more potent IMiD, pomalidomide, in combination in those patients who are lenalidomide refractory. (ajmc.com)
  • The programmed death-1 inhibitors nivolumab and pembrolizumab have both demonstrated high response rates and durable remissions in patients with relapsed/refractory HL. (johnshopkins.edu)
  • Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. (smw.ch)
  • High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. (smw.ch)
  • High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma. (smw.ch)
  • The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups. (smw.ch)
  • Updated results will also be presented from a phase 1 study of the investigational agent SEA-BCMA in patients with relapsed/refractory multiple myeloma. (businesswire.com)
  • Life expectancy of patients diagnosed with new, relapsed-refractory or secondary AML has been improved by drugs targeted at such moieties. (journaltocs.ac.uk)
  • Adding thalidomide to a standard regimen of high-dose chemotherapy in patients with the cancer multiple myeloma improved complete responses but did not give any advantage in five-year survival, according to a study published in the New England Journal of Medicine (March 9). (pharmatimes.com)
  • Thalomid was also associated with higher event-free survival at five years (56% versus 43%), but the overall survival rate was no different at 65% a piece. (pharmatimes.com)
  • The estimated event-free survival rate (+/-SD) at five years was significantly higher among patients who received high-dose therapy than among patients who received CHOP (55+/-5 percent vs. 37+/-5 percent, P=0.037). (qxmd.com)
  • Among patients with a high intermediate risk of death, according to the age-adjusted International Prognostic Index, the five-year survival rate was significantly higher after high-dose therapy than after CHOP (74+/-6 percent vs. 44+/-7 percent, P=0.001). (qxmd.com)
  • The actuarial event-free survival for these 56 patients at 3 years was 37% and was at least as good as that reported for relapsed Hodgkin's disease patients treated with CBV and ABMT. (shengsci.com)
  • The 30 patients who had no marrow metastases at the time of PSC harvesting had an actuarial event-free survival of 47%, while those 26 patients with marrow metastases had a significantly different actuarial event-free survival of 27% (P = .02). (shengsci.com)
  • CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival. (shengsci.com)
  • Patients with resistant or relapsed (r/r) DLBCL have a poor prognosis with a median overall survival of 6,3 months and low complete response rates (CR 7%) to salvage chemoimmunotherapy. (deepdyve.com)
  • Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. (smw.ch)
  • 12 Over the past decade, however, survival of patients with MM has improved dramatically with the advent of newer therapies. (touchoncology.com)
  • The objective response rate, progression-free survival, and overall survival were analyzed for each patient cohort. (biomedcentral.com)
  • This study provided Class III evidence that the teniposide-based regimen was non-inferior to high-dose methotrexate − based regimen with similar overall responses and long-time survival in immunocompetent patients with PCNSL. (biomedcentral.com)
  • The purpose of this study is to evaluate the effectiveness of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. (mayo.edu)
  • The primary purpose of this study is to estimate and compare overall survival between the two arms: patients who are Very Likely to find a Matched Unrelated Donor (MUD) versus those who are Very Unlikely to find a MUD. (mayo.edu)
  • Results showed that 3-year event-free survival was 48.4% ± 3.8% with single autologous HCT compared with 61.4% ± 3.7% with tandem autologous HCT ( P =.0081). (oncologynurseadvisor.com)
  • The study further demonstrated that tandem autologous HCT also benefits patients who received immunotherapy, with a significant difference in 3-year event-free survival between the 2 treatment arms ( P =.0033). (oncologynurseadvisor.com)
  • Single-agent chemotherapy improved the average survival to four months and the development of combination chemotherapy regimens has further increased the average survival to approximately nine months with some patients surviving two years or longer. (yourcancercare.com)
  • Targeted therapies are anticancer drugs that interfere with specific pathways involved in cancer cell growth or survival. (yourcancercare.com)
  • The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • BEXXAR is also currently being tested in a Phase III trial in the Bone Marrow Transplant Clinical Trials Network (BMT/CTN) of Rituximab + BEAM vs. BEXXAR + BEAM in patients with relapsed DLBCL. (salesandmarketingnetwork.com)
  • Bone marrow transplantation , 37 (10), 929-935. (elsevierpure.com)
  • Hodgkin lymphoma is a localized or disseminated malignant proliferation of cells of the lymphoreticular system, primarily involving lymph node tissue, spleen, liver, and bone marrow. (msdmanuals.com)
  • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (smw.ch)
  • The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. (smw.ch)
  • Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. (smw.ch)
  • High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. (smw.ch)
  • High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich. (smw.ch)
  • The procedure of bone marrow / peripheral stem cell transplantation serves as a pivotal treatment avenue for patients contending with a spectrum of medical challenges. (medistateinternational.com)
  • While alternative therapeutic techniques persist, bone marrow/peripheral stem cell transplantation emerges as a transformative option, particularly when other methods display limited efficacy. (medistateinternational.com)
  • For conditions affecting the bone marrow-the essential hub for blood cell production-stem cell transplantation emerges as a potential avenue for patients grappling with insufficient or impaired blood production. (medistateinternational.com)
  • While some of these conditions show resistance to the benefits of bone marrow transplantation, others possess mild courses that don't necessitate transplantation. (medistateinternational.com)
  • This twofold approach not only harnesses the power of potent chemotherapy but also safeguards against bone marrow deficiency by replenishing the patient's stem cell count following the chemotherapy phase. (medistateinternational.com)
  • Bone marrow transplantation , 16 (1), 13-18. (umn.edu)
  • Bone Marrow Transplantation (2000) 26, 877-880. (nature.com)
  • Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. (nature.com)
  • Biology of Blood and Marrow Transplantation , 25 (7), 1312-1319. (elsevierpure.com)
  • The primary purpose of this study is to demonstrate the feasibility of sublingual (SL) administration of tacrolimus in blood and marrow transplant (BMT) patients. (mayo.edu)
  • The purpose of this study is to evaluate the effects that psychological and health behavior factors have on quality of life, level if sickness, and death after blood and bone marrow transplantation. (mayo.edu)
  • Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion. (mims.com)
  • Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (merckmanuals.com)
  • Lymphatic tissues also include the thymus, a relatively small organ behind the breastbone that is thought to play an important role in the immune system until puberty, as well as the bone marrow, which is the spongy tissue inside the cavities of bones that manufactures blood cells. (rarediseases.org)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • For patients who achieved complete remission, the median time before their disease progressed was 9.2 years. (salesandmarketingnetwork.com)
  • Thirty patients had complete remission, eight had a PR, one had a minor response, and three had progressive disease. (elsevierpure.com)
  • Similarly, pembrolizumab demonstrated an overall response rate (ORR) of 69% with a complete remission rate (CRR) of 22.4% in the KEYNOTE-087 study in heavily pretreated patients with rrcHL. (wjon.org)
  • With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
  • He remains in complete remission 2 years after transplantation. (elsevierpure.com)
  • Overall, COP chemotherapy causes complete remission in about 70% of dogs with lymphoma for a median of 130 days. (vin.com)
  • OBJECTIVE: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. (bvsalud.org)
  • 110 dogs were treated with a sequential chemotherapy protocol that used the above drugs (Madison-Wisconsin Protocol or AMC protocol). (vin.com)
  • Clinical trials continue to evaluate new drugs and new combinations of drugs in an effort to improve upon the treatment results achieved with standard chemotherapy regimens. (yourcancercare.com)
  • All patients (106 with high-grade non-Hodgkin lymphoma and 77 with Hodgkin's lymphoma) submitted to this treatment between 1998 and 2006 were analyzed. (bvsalud.org)
  • GSK News) announced today long-term efficacy data from a Phase II trial of a single one-week course of frontline treatment with the BEXXAR Therapeutic Regimen (Tositumomab and Iodine I-131 Tositumomab) in 76 patients with newly diagnosed advanced follicular non-Hodgkin's lymphoma (NHL). (salesandmarketingnetwork.com)
  • Of note, these results were achieved with BEXXAR given as a single treatment, completed within one week, which made it a convenient regimen for these patients," said Mark Kaminski, Professor of Internal Medicine and Director, Leukemia/Lymphoma Program at the University of Michigan and lead investigator of this study. (salesandmarketingnetwork.com)
  • GSK is proud to be a leading developer of new medicines, like BEXXAR, for patients battling lymphoma, and these results support our ongoing development plan investigating additional patient populations that may benefit from this important therapy. (salesandmarketingnetwork.com)
  • Hodgkin lymphoma results from the clonal transformation of cells of B-cell origin, giving rise to pathognomic binucleated Reed-Sternberg cells. (msdmanuals.com)
  • Most patients with Hodgkin lymphoma present with painless cervical adenopathy. (msdmanuals.com)
  • The overall prognosis of patients with relapsing and recurrent classical Hodgkin lymphoma (rrcHL) has been very disappointing until recently. (wjon.org)
  • Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. (qxmd.com)
  • The patients were 15 to 60 years of age, had untreated aggressive lymphoma, and were at low, low intermediate, or high intermediate risk of death (i.e., a maximum of two adverse prognostic factors) according to the age-adjusted International Prognostic Index. (qxmd.com)
  • High-dose chemotherapy with autologous stem-cell support is superior to CHOP in adults with disseminated aggressive lymphoma. (qxmd.com)
  • Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous Reed-Sternberg cells in an inflammatory background. (johnshopkins.edu)
  • SummaryDiffuse large B‑cell lymphoma (DLBCL) comprises 30-40% of non-Hodgkin's lymphoma. (deepdyve.com)
  • Initial lymphoma stage and number of previous treatment lines were identified as independent risk factors for EFS in DLBCL and HL patients. (smw.ch)
  • The abstracts, including five oral presentations, highlight updated and interim efficacy and safety clinical trial results for ADCETRIS in both early- and advanced stage settings of classical Hodgkin lymphoma (cHL), and in patients with other CD30-expressing lymphomas and other rare cancers. (businesswire.com)
  • In a comparative study, researchers analyzed the efficacy and safety of flumustine, teniposide, and dexamethasone in patients with central nervous system lymphoma (CNSL). (biomedcentral.com)
  • Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. (unicatt.it)
  • Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). (ashpublications.org)
  • Martí-Carvajal AJ, Cardona AF, Lawrence A. Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma. (medscape.com)
  • Serum Levels of the Chemokine CXCL13, Genetic Variation in CXCL13 and Its Receptor CXCR5, and HIV-Associated Non-Hodgkin B-Cell Lymphoma Risk. (medscape.com)
  • Lymphoma is the most common haematopoietic malignancy in dogs, and is the most responsive to chemotherapy. (vin.com)
  • Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma, which is a form of cancer that affects the lymphatic system. (rarediseases.org)
  • MCL is a B-cell lymphoma that develops from malignant B-lymphocytes within a region of the lymph node known as the mantle zone. (rarediseases.org)
  • Mantle cell lymphoma belongs to a group of diseases known as non-Hodgkin's lymphomas, which are related malignancies (cancers) that affect the lymphatic system. (rarediseases.org)
  • The value of CD23 expression as an additional marker in distinguishing mediastinal (thymic) large B-cell lymphoma from Hodgkin lymphoma. (pharmateca.ru)
  • Primary mediastinal large B-cell lymphoma. (pharmateca.ru)
  • A regimen of bortezomib and dexamethasone has also been examined. (wikipedia.org)
  • Increased class 1 HDAC expression has been linked in solid tumours with more locally advanced, de-differentiated and proliferative tumours, and with poor prognosis in MM. HDAC inhibitors, panobinostat and ricolinostat, have been demonstrated to be effective in combination with bortezomib and dexamethasone in newly diagnosed patients with MM and in heavily pre-treated patients with advanced MM. HDAC inhibitor-monoclonal antibody combinations are also being explored. (touchoncology.com)
  • The National Cancer Institute's Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J. (medscape.com)
  • This regimen was found to induce durable clinical and molecular remissions in patients with this disease. (salesandmarketingnetwork.com)
  • This is particularly apparent from the entree of high-throughput diagnostic technologies and the identification of prognostic and therapeutic targets, the introduction of therapies in genetically defined subgroups of AML, as well as the influx of investigational approaches and novel drugs into the pipeline of clinical trials that target pathogenetic mechanisms of the disease. (ashpublications.org)
  • PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-line Treatment of Subjects With A Phase 3 Clinical Trial Comparing Infusional 5 Fluorouracil, Leucovorin, and Oxaliplatin. (med-abstracts.com)
  • Several patients with clinical features of chronic myeloid leukemia (CML) have fusion of the TEL (ETV6) gene on 12p13 with ABL on 9q34 and express a chimeric Tel-Abl protein that contains the same portion of the Abl tyrosine kinase fused to Tel, an Ets family transcription factor, rather than Bcr. (shengsci.com)
  • Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. (shengsci.com)
  • Eighty-two patients with advanced multiple myeloma (MM) were enrolled in 2 sequential clinical studies of 1 or 2 courses of myeloablative therapy with stem cell support. (shengsci.com)
  • Immuno-oncology has entered the field, and besides the checkpoint death receptor and ligand molecules PD-1/PD-L1 more molecules have been detected and are also tested in clinical studies.To provide equal opportunities to our patients the tests have to be implemented in all pathological institutes involved in lung cancer management. (deepdyve.com)
  • Clinical factors such as a high International Prognostic Index (IPI) or molecular factors as cell of origin (COO) have an influence on the clinical outcome after conventional immunochemotherapy. (deepdyve.com)
  • Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. (smw.ch)
  • Unfortunately, the term is often used to describe any patient with a TMA who does not have severe ADAMTS13 deficiency or a documented Shiga toxin, therefore it has little clinical usefulness. (medilib.ir)
  • Multiple myeloma (MM), a clonal expansion of plasma cells, is characterised by monoclonal protein production, end-organ damage and marked clinical and genetic heterogeneity. (touchoncology.com)
  • For these reasons, the development of more effective and less toxic novel therapeutic regimens for PCNSL is of great clinical importance. (biomedcentral.com)
  • Twenty-three (37%) patients remain in continuous clinical remission 1.3 to 7.7 years (median 3.8 years) after transplantation. (umn.edu)
  • Additionally, we present a comparison of the clinical characteristics and outcomes of these patients and those of patients with benign neurogenic tumors (BNTs) resected at our institution. (springeropen.com)
  • Many of the clinical complications of PV relate directly to the increase in blood viscosity associated with red cell mass elevation and indirectly to the increased turnover of red cells, leukocytes, and platelets with the attendant increase in uric acid and cytokine production. (basicmedicalkey.com)
  • Patients who are interested in participating in a clinical trial should discuss the risks and benefits of clinical trials with their physician. (yourcancercare.com)
  • The progress that has been made in the treatment of small cell lung cancer has resulted from the development of multi-modality treatments, new anti-cancer agents and participation in clinical trials. (yourcancercare.com)
  • Future progress in the treatment of small cell lung cancer will result from continued participation in appropriate clinical trials. (yourcancercare.com)
  • Giant cell tumors (GCT) of the bone are aggressive and are recognised for variable clinical behaviour, which is not always related to radiographic or histological appearance [1]. (jbstjournal.com)
  • clinical conditions of the patient, the existence of a tumors are considered rare (KLUSMANN et al. (bvsalud.org)
  • The toxicities reported are predominantly cytopenias, which require white blood cell growth factor support to all patients. (expertperspectives.com)
  • Thus, we need to take the toxicity profile into consideration when selecting a treatment since it may be difficult to manage these toxicities when severe, especially in older patients. (expertperspectives.com)
  • We conclude that in spite of rapid engraftment, non-hematological toxicities and infections remain important limitations for further reduction of the length of patient hospitalization in a significant number of patients after PBSCT. (nature.com)
  • No dose-limiting toxicities were observed. (elsevierpure.com)
  • Phase 1b will assess dose-limiting toxicities of PF-07901801 when administered in combination with glofitamab, to select up to 2 doses for the Phase 2 part of the study. (survivornet.com)
  • Toxicities that required dose reduction occurred in 40% of the dogs. (vin.com)
  • Gastrointestinal toxicities were the most frequent (97.1%) and all patients received antineoplastic/chemotherapeutic and antiemetic treatment. (bvsalud.org)
  • Although the same doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapeutic regimen has been the mainstay of therapy over the last 30 years, risk-adapted approaches have helped de-escalate therapy in low-risk patients while intensifying treatment for higher risk patients. (johnshopkins.edu)
  • CONCLUSION: We demonstrated a clear reduction of unfavorable outcomes in patients receiving prophylactic transfusions, probably reflecting better maternal and fetal conditions, which corroborated to the more satisfactory indices of vitality, observed in newborns. (bvsalud.org)
  • However, as the outcomes for patients with low- and intermediate-risk disease are similar, these categories have been collapsed into one and considered as low-risk disease. (nature.com)
  • Because pilot studies of tandem autologous HCT demonstrated tolerable toxicity and potential efficacy and because prior trials have demonstrated that dose intensification improves outcomes, researchers decided to explore tandem transplantation in patients with high-risk neuroblastoma. (oncologynurseadvisor.com)
  • Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
  • Efforts to overcome chemotherapy resistance by including multidrug resistance modifiers (e.g., cyclosporin or its analogue PSC 833) in the induction schedule have as yet not met with reproducible success in prospective comparative studies. (ashpublications.org)
  • The patients received HD-MTX or TEN as first-line induction therapy. (biomedcentral.com)
  • Most regimens of induction chemotherapy include drugs that cross the blood-brain barrier (BBB) in conventional doses. (biomedcentral.com)
  • Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. (ashpublications.org)
  • Most, if not all, regimens in the newly diagnosed setting, whether it's part of a 3- or 4-drug therapy, will contain the most commonly prescribed IMiD in the United States, which is lenalidomide. (ajmc.com)
  • In the past two decades, therapy for newly diagnosed APL has evolved from an all- trans retinoic acid (ATRA)+chemotherapy backbone for all patients to the addition of arsenic trioxide (ATO) to ATRA with omission of chemotherapy in low-risk patients as a new standard of care. (nature.com)
  • This study aimed to compare the efficacy and safety of high-dose methotrexate (HD-MTX) versus teniposide (TEN) in patients with newly diagnosed immunocompetent primary central nervous system lymphomas (PCNSLs). (biomedcentral.com)
  • The study included immunocompetent, adult patients with newly diagnosed PCNSL at 22 centers in China from 2007 to 2016. (biomedcentral.com)
  • The standard therapeutic regimens for newly diagnosed PCNSL have not been well defined. (biomedcentral.com)
  • For the study, researchers enrolled 355 children (median age, approximately 3 years) who were newly diagnosed with high-risk neuroblastoma. (oncologynurseadvisor.com)
  • Check specific guidelines for restaging and dosage adjustments for chemotherapy and/or radiation therapy depending on positron-emission tomography (PET) scanning throughout the various regimens. (medscape.com)
  • Regimens that combine chemotherapy and radiation therapy (RT) have replaced RT alone for treatment of early-stage, favorable disease. (medscape.com)
  • Involved-site radiation therapy (ISRT) is typically recommended, because high-dose, large-field radiation therapy (LFRT) increases risk for heart disease, pulmonary dysfunction, and secondary cancers. (medscape.com)
  • Additionally, 50% of patients survived without progression of disease at 8 years following therapy. (salesandmarketingnetwork.com)
  • The best response after surgery, HDCT, and radiation therapy was assessed 60 days after transplantation. (elsevierpure.com)
  • Treatment is curative in most cases and consists of chemotherapy with or without other treatment modalities, including antibody-drug conjugates, immunotherapy, and radiation therapy. (msdmanuals.com)
  • In Section II, Dr. James Griffin reviews the mechanisms that lead to activation of tyrosine kinases by mutations in AML, the consequences of that activation for the cell, and the opportunities for targeted therapy and discusses some examples of developing novel drugs (tyrosine kinase inhibitors) and their effectiveness in AML (FLT3). (ashpublications.org)
  • Multiple lines of therapy are available for patients after their first failure, and most respond to subsequent therapies. (wjon.org)
  • The present modalities of therapy have converted a fatal disease to one that is curable in most patients. (wjon.org)
  • These are intensive chemotherapy regimens that, on one level, serve to identify patients who can tolerate such therapy, and they may offer potent cytoreduction, with the quality of remission being the biggest predictor of success with subsequent high-dose chemotherapy and autologous stem cell transplantation. (expertperspectives.com)
  • Identification of patients at risk of central nervous system disease is critical to accurately identify candidates for central nervous system prophylaxis vs. therapy. (haematologica.org)
  • In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
  • Three days after starting high-dose therapy, he developed a fever, and a chest X-ray revealed pneumonia in the right lower lung. (elsevierpure.com)
  • Safe administration of CAR-T cell therapy requires thorough patient selection and patient care in qualified CAR-T cell centers. (deepdyve.com)
  • The decision to proceed with transplantation hinges on a thorough assessment of patients' chances for successful results, along with a comprehensive understanding of therapy-related risks. (medistateinternational.com)
  • One patient with local recurrence underwent radiation therapy, but the recurrent tumor continued to progress. (springeropen.com)
  • The patient received liver support therapy, and the serum hepatic enzymes recovered to normal levels. (journaltocs.ac.uk)
  • Are unable or unwilling to undergo a stem cell transplant or CAR-T cell therapy. (survivornet.com)
  • A CAR-T therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. (survivornet.com)
  • Consolidative radiation therapy was given to patients with mediastinal disease at presentation. (ashpublications.org)
  • 15. Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. (whocc.org.cn)
  • Staging carries prognostic significance and enables the veterinarian and client to make informed and rational decisions as to the type of therapy best suited for the patient. (vin.com)
  • Prognostic factors include stage and substage of disease, histologic type, immunophenotype (B-cell versus T-cell), presence of hypercalcemia, response to therapy, pre-treatment steroid therapy, and possibly gender. (vin.com)
  • Less than 50% of children with high-risk neuroblastoma will survive following current multi-agent, aggressive therapy. (oncologynurseadvisor.com)
  • In the single autologous HCT arm, 129 of the 179 patients were subsequently given dinutuximab, an anti-GD2 monoclonal antibody, plus cytokine immunotherapy after single transplant consolidation therapy. (oncologynurseadvisor.com)
  • Similarly, 121 of the 176 patients in the other arm received this immunotherapy after double transplant consolidation therapy. (oncologynurseadvisor.com)
  • I think adding proteasome inhibitors-in this case it was carfilzomib, but bortezomib has been shown to be effective as a maintenance therapy for high-risk patients-to lenalidomide makes a lot of sense. (targetedonc.com)
  • Although the incidence of acute nonlymphocytic leukemia is increased in PV, the incidence of acute leukemia in patients not exposed to chemotherapy or radiation therapy is low. (basicmedicalkey.com)
  • Some patients with extensive small cell lung cancer also receive radiation therapy. (yourcancercare.com)
  • HSCT patients are presumed immunocompetent if they are at least 24 months post-HSCT, are not receiving immunosuppressive therapy, and do not have graft- versus-host disease (GVHD). (cdc.gov)
  • progression on treatment or within 60 days of stopping a bortezomibor carfilzomib-based regimen as last line of therapy. (who.int)
  • Historically, APL has been characterized by a rapidly fatal course with a high incidence of early hemorrhagic death. (nature.com)
  • APL has been associated with a high incidence of early hemorrhagic death. (nature.com)
  • In order to assess the incidence and analyze reasons which cause prolongation of hospital stay in patients engrafted after peripheral blood stem cell transplantation (PBSCT), we performed this retrospective analysis. (nature.com)
  • boxers, Scottish terriers, German shepherds and poodles were more often affected, and recent evidence suggests a high incidence in golden retrievers. (vin.com)
  • Peptic ulcer disease can also be due to Helicobacter pylori infection, the incidence of which is increased in PV, while the pruritus associated with this disorder may be a consequence of mast cell activation by JAK2 V617F. (basicmedicalkey.com)
  • Body iron disorders have been reported after myeloablative conditioning in patients undergoing hematopoietic stem cell transplantation (HSCT). (karger.com)
  • In order to better understand the LPI kinetics and its determinants and implications, we undertook sequential LPI determinations before and after conditioning until engraftment in 25 auto-HSCT patients. (karger.com)
  • The purpose of this study is to measure the effect of Hematopoietic Stem Cell Transplantation (HSCT) on symptoms of CSF1R-related Leukoencephalopathy. (mayo.edu)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • and phase mended strategies for preventing OIs in HSCT patients. (cdc.gov)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The final sample consisted of 35 records patients aged between 2 and 18 years old who underwent HSCT from February 2008 to December 2015 and who presented the data necessary for the study. (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • Earlier application of transplantation or development of additional effective antineoplastic modalities will be required to improve the results of transplantation for patients with advanced Hodgkin's disease. (umn.edu)
  • The safety, tolerability, and toxicity management of therapies for DLBCL are part and parcel with efficacy in considering selection among treatment regimens. (expertperspectives.com)
  • A subsequent cohort with 41 patients was analyzed in a phase II trial to identify safety and efficacy. (elsevierpure.com)
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
  • The belief that T-cell lymphomas have a worse prognosis than B-cell lymphomas remains controversial. (oncolink.org)
  • REAL/WHO- [6] - classification includes leukemias and lymphomas, with 3 categories based on lineage and morphology (Hodgkin, B cell, and T/NK cell). (oncolink.org)
  • Lymphomas are cancers that involve white blood cells, and can be divided depending on the type of cell involved, either B-lymphocytes or T-lymphocytes. (rarediseases.org)
  • MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. (pharmateca.ru)
  • Patients are commonly diagnosed with HL in their 20s and 30s, and they present with supradiaphragmatic lymphadenopathy, often with systemic B symptoms. (johnshopkins.edu)
  • INTRODUCTION - The initial evaluation of a patient with suspected thrombotic thrombocytopenic purpura (TTP) or another primary thrombotic microangiopathy (TMA) syndrome must focus on distinguishing these primary syndromes from other systemic disorders that can present with microangiopathic hemolytic anemia (MAHA) and thrombocytopenia. (medilib.ir)
  • Other systemic disorders that can present with MAHA and thrombocytopenia include pregnancy-associated syndromes (eg, preeclampsia with severe features and HELLP syndrome), severe hypertension, systemic infections and malignancies, autoimmune disorders such as systemic lupus erythematosus, and complications of hematopoietic stem cell or solid organ transplantation. (medilib.ir)
  • For Phase 1b, participants must have previously received at least 1 prior systemic treatment regimen. (survivornet.com)
  • For Phase 2, participants must have received at least 1 but no more than 2 prior systemic treatment regimens. (survivornet.com)
  • Two died while receiving high-dose systemic corticosteroids, methotrexate, and after recent exposure to anti-tumor necrosis factor-α biological DMARDs, and 2 during hematopoietic stem cell transplantation procedure. (cdc.gov)
  • Combined, these agents form a radiolabeled monoclonal antibody regimen that is able to bind to the target antigen CD20 found on B cells, including normal B-cells and those that become cancerous in NHL, thereby delivering the dose of radiation. (salesandmarketingnetwork.com)
  • BEXXAR, which is given in four visits over one to two weeks, is specifically dosed based on an individual's drug clearance rate, allowing the delivery of a predetermined amount of radiation to each patient. (salesandmarketingnetwork.com)
  • Even in advanced-stage disease, HL is highly curable with combination chemotherapy, radiation, or combined-modality treatment. (johnshopkins.edu)
  • MATERIALS AND METHODS: Patients were divided into two groups according to the type of transfusion support received: 10 women received prophylactic erythrocytapheresis or manual exchange transfusion at 28 weeks of gestation, and 14 received transfusions only on demand, due to acute complications, or received no transfusions at all. (bvsalud.org)
  • The therapeutic approach to the patient with acute myeloid leukemia (AML) currently evolves toward new frontiers. (ashpublications.org)
  • In Section III, Dr. Martin Tallman describes the evaluation and management of patients with acute promyelocytic leukemia, a notable example of therapeutic progress in a molecularly defined entity of leukemia. (ashpublications.org)
  • Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. (shengsci.com)
  • Previous studies have shown that children with acute myeloid leukemia (AML) who developed mixed chimerism (MC) were at high risk for relapse after allogeneic stem-cell transplantation (allo-SCT). (shengsci.com)
  • INITIAL EVALUATION (ALL PATIENTS) - Individuals with a TMA may come to medical attention with any of a variety of presentations including unexplained anemia or thrombocytopenia, unexplained neurologic findings (suspected stroke or transient ischemic attack), or other acute illness. (medilib.ir)
  • Misdiagnosis of acute hepatitis E virus (HEV) infection as drug-induced liver injury (DILI) may lead to discontinuation of effective chemotherapy. (journaltocs.ac.uk)
  • Interestingly, chemotherapy, including hydroxyurea, has been associated with acute leukemia in JAK2 V617F-negative stem cells in some PV patients. (basicmedicalkey.com)
  • It permits the administration of exceedingly high doses of chemotherapy, a practice that becomes viable due to the subsequent infusion of the patient's own stem cells. (medistateinternational.com)
  • Chemotherapy was resumed without any subsequent relapse of hepatic enzyme elevation. (journaltocs.ac.uk)
  • The combination treatment was also associated with higher rates of blood clots and damage to the nerves. (pharmatimes.com)
  • Thalidomide, originally used as a treatment for morning sickness, was taken off the market in the 1960s because women who took it during pregnancy had a much higher rate of severe birth defects. (pharmatimes.com)
  • High-dose chemotherapy (using a different chemotherapeutic agent) and autologous stem cell transplantation (SCT) is considered the treatment of choice in a subset of patients. (wjon.org)
  • Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. (smw.ch)
  • See "HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets)" and "Evaluation and treatment of hypertensive emergencies in adults" and "Catastrophic antiphospholipid syndrome (CAPS)" and "Early complications of hematopoietic cell transplantation", section on 'Thrombotic microangiopathy' . (medilib.ir)
  • There is a critical need for more effective therapies in multiple myeloma (MM) since all patients eventually relapse following front-line treatment. (touchoncology.com)
  • 14-17 Front-line treatment of MM can result in high response rates, 18-21 although all patients eventually relapse and more effective therapies are needed. (touchoncology.com)
  • For certain types of leukemia, conventional chemotherapy methods present a viable treatment avenue. (medistateinternational.com)
  • Often, conventional medical treatment options are limited, leaving stem cell transplantation as a potential game-changer. (medistateinternational.com)
  • Among them, a significant portion of elderly patients aged 70 or older cannot tolerate HD-MTX, and other equivalent drugs or treatment options for those patients are currently lacking. (biomedcentral.com)
  • In a univariate analysis, factors significantly associated with improved DFS included absence of B symptoms (fever, night sweats and unexplained weight loss) at transplant, response to pre-transplant salvage chemotherapy, less tumor bulk at time of transplant, and fewer prior treatment regimens. (umn.edu)
  • Although all three lesions were completely excised, each patient relapsed within 1 year of the initial treatment. (springeropen.com)
  • Although the relapsed lesions temporarily regressed after treatment, all three patients showed disease recrudescence and ultimately died of their disease. (springeropen.com)
  • The patient received postoperative radiotherapy as an adjuvant treatment, but it was discontinued halfway through when multiple bone metastases were identified. (springeropen.com)
  • Stem cell transplant is a procedure in which a patient receives healthy blood-forming cells to replace their own stem cells that have been destroyed by treatment. (survivornet.com)
  • At Cycle 0, participants will receive a single dose of obinutuzumab pre-treatment followed by two step-up doses of glofitamab. (survivornet.com)
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • Once a definitive diagnosis has been obtained and after the patient has been staged accurately, the veterinarian should schedule a discussion with the owner regarding prognosis and treatment. (vin.com)
  • The first-line treatment typically includes chemotherapy combined with immunotherapy, which is a combination of medications that destroy the cancer cells. (rarediseases.org)
  • The following is a general overview of the treatment of extensive small cell lung cancer. (yourcancercare.com)
  • Patients with extensive disease small cell lung cancer are rarely curable with currently available standard treatment strategies although many patients experience a response to treatment. (yourcancercare.com)
  • This preventive treatment-called prophylactic cranial irradiation-is usually reserved for patients who have had a good response to chemotherapy. (yourcancercare.com)
  • While some progress has been made in the treatment of small cell lung cancer, better treatment strategies are clearly needed, as the majority of patients still experience disease recurrence. (yourcancercare.com)
  • There are several areas of active exploration aimed at improving the treatment of small cell lung cancer. (yourcancercare.com)
  • Periodic phlebotomies thereafter serve to maintain the red cell mass within the normal range and to induce a state of iron deficiency that prevents an accelerated reexpansion of the red cell mass. (basicmedicalkey.com)
  • With tafasitamab plus lenalidomide, you can see infusion reactions from the monoclonal antibody, but most of the toxicity comes from lenalidomide (eg, cytopenias, rash, and diarrhea), which often results in lenalidomide dose reductions. (expertperspectives.com)
  • Lenalidomide also increases the risk of thrombosis, so thromboprophylaxis should be given to all patients, usually with a low-dose aspirin. (expertperspectives.com)
  • Outside of the United States, because of cost restraints, it is much more common to use thalidomide-based regimens than lenalidomide-based regimens. (ajmc.com)
  • Finally, all patients were put on [10-15 mg daily] lenalidomide maintenance for a year. (targetedonc.com)
  • Finally, there was a second randomization for the maintenance drug, which could be lenalidomide alone or combined with carfilzomib, with the carfilzomib being given in a cumbersome way for patients where they get 4 doses of carfilzomib a month for 2 years. (targetedonc.com)
  • In the second randomization, the patients who got carfilzomib combined with lenalidomide had a better PFS than those on lenalidomide alone, with benefits both for standard- and high-risk cytogenetics. (targetedonc.com)
  • So I think it's clear that lenalidomide alone isn't adequate if patients have high-risk disease. (targetedonc.com)
  • The five-year study revealed that the complete response rate among the Thalomid group, defined as the disappearance of malignant cells in the blood, was 62%, significantly higher than the 43% seen in the control group. (pharmatimes.com)
  • The nature of disease (indolent vs. aggressive) is correlated to the stage of lymphocytic differentiation of the malignant cells. (oncolink.org)
  • We present three patients with intrathoracic malignant neurogenic tumor. (springeropen.com)
  • Because there is no effective chemotherapeutic regimen for intrathoracic malignant neurogenic tumor, all three patients received high-dose chemotherapy followed by hematopoietic stem cell transplantation. (springeropen.com)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
  • Giant cell tumor is a benign bone tumor, locally aggressive with low malignant potential. (jbstjournal.com)
  • There were no deaths resulting from toxicity of the preparative regimen, and all patients survived the peritransplant period. (umn.edu)
  • I recommend pneumocystis and antiviral prophylaxis for all of my patients who are receiving bendamustine. (expertperspectives.com)
  • Options include chemotherapy using bortezomib, autologous stem cell transplantation, immunomodulatory drugs, and kidney transplant. (wikipedia.org)
  • Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM. (ajmc.com)
  • Enhancement of human erythroid progenitor cell growth by media conditioned by a human t-lymphocyte line. (shengsci.com)
  • During a Targeted Oncology case-based roundtable event, Robert A. Vescio, MD, discussed the results of several key trials related to new treatments for patients with transplant-eligible multiple myeloma. (targetedonc.com)
  • Everyone taking part will receive the same fixed doses of glofitamab and obinutuzumab studied in patients with DLBCL. (survivornet.com)